News

Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Eli Lilly stock slips despite earnings beat, reaffirmed 2025 guidance
Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.
Stock Movers: Eli Lilly, Qualcomm, Carrier Global
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Eli Lilly CEO says tariffs are not the answer, urges Trump to move fast on trade deals
Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.
Lilly cuts earnings guidance on research costs, shares fall
Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...